GDM at Fasting Glucose 88 — The Threshold Problem

Presentation

4,200 SA singleton pregnancies from centers in the UK, Canada, and India underwent universal early and 24-28 week OGTT screening. Maternal characteristics, fasting glucose, 1-hour and 2-hour OGTT results, and detailed neonatal outcomes (birth weight, hypoglycemia, jaundice, NICU admission) were collected.

Key Finding

Among mothers WITHOUT GDM by current criteria, those with fasting glucose 88-91 had: macrosomia rate 9.4% vs 4.1% in <85 group (p < 0.001); LGA infants 14% vs 7%; neonatal hypoglycemia 5.8% vs 2.1%; NICU admission 11% vs 6%. Hyperglycemia and Adverse Pregnancy Outcomes (HAPO)-style continuous risk modeling showed inflection in adverse outcomes beginning at fasting glucose 84 mg/dL in SA women, vs 92 in the original European cohort.

Intervention & Outcome

Observational study, no intervention. The clinical implication: SA pregnancies should receive enhanced screening and possibly earlier glycemic intervention at lower glucose thresholds. Current IADPSG criteria (fasting ≥92) miss a substantial population of SA women whose pregnancies would benefit from medical nutrition therapy and glucose monitoring.

First Principles

In pregnancy, placental hormones (hPL, cortisol, progesterone) induce maternal insulin resistance to redirect glucose to the fetus. Healthy beta cells compensate by doubling insulin output. The Fragile Engine (limited beta-cell reserve) decompensates at smaller insulin demand. Modest maternal hyperglycemia drives fetal hyperinsulinemia, which in turn drives fat deposition and somatic overgrowth. The thresholds at which fetal harm begins are biological, not statistical — and they're lower for fragile-engine populations.